Novo Invests $2.3 Billion in France for Obesity Drug Production

Novo Nordisk has announced a $2.3 billion investment to boost production of its wildly popular weight-loss and diabetes drugs at a site in Chartres, France.

Related Keywords

Germany ,Belgium ,France ,Paris ,France General ,Denmark ,United Kingdom ,French ,British ,Danish ,Eli Lilly ,Novo Nordisk ,Ludwig Burger ,David Goodman ,Terje Solsvik ,Anna Ringstrom ,Lars Fruergaard Jorgensen ,Emelia Sithole Matarise ,Reuters ,European Union ,French President Emmanuel Macron ,Fruergaard Jorgensen ,Weight Management ,Obesity ,Bese ,Investment ,Glp 1 Receptor Agonists ,Glucagon Like Peptide 1 Receptor Agonists ,Drug Shortages ,Medication Shortages ,Incretin Hormones ,Incretins ,Weight Loss ,Europe ,European ,Off Label Indication ,Diabetes Mellitus Type 2 ,Iabetes Mellitus Type Ii ,Type 2 Diabetes ,Ype 2 Dm ,T2dm ,2d ,